Xu-Monette, Z. Y., Li, J., Xia, Y., Crossley, B., Bremel, R. D., Miao, Y., Xiao, M., Snyder, T., Manyam, G. C., Tan, X., Zhang, H., Visco, C., Tzankov, A., Dybkaer, K., Bhagat, G., Tam, W., You, H., Hsi, E. D., van Krieken, J. H., Huh, J., Ponzoni, M., Ferreri, A. J. M., Møller, M. B., Piris, M. A., Winter, J. N., Medeiros, J. T., Xu, B., Li, Y., Kirsch, I., & Young, K. H. (2019). immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies. Journal for immunotherapy of cancer, 7(1), . http://access.bl.uk/ark:/81055/vdc_100144511408.0x000016